Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H Mutation

Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H Mutation

We report the case of a patient with appendiceal adenocarcinoma with mucinous peritoneal carcinomatosis who was treated with trametinib upon identification of a GNAS R201H mutation by comprehensive genomic profiling. The molecular pathology of appendiceal neoplasms is reviewed, and the mechanistic b...

Full description

Bibliographic Details
Main Authors: Celina Ang, Aryeh Stollman, Hongfa Zhu, Umut Sarpel, Bethann Scarborough, Gagan Sahni, Sherri Z. Millis
Format: Article
Language:English
Published: Karger Publishers 2017-06-01
Series:Case Reports in Oncology
Subjects:
Targeted therapy
Appendiceal adenocarcinoma
GNAS mutation
Trametinib
Online Access:http://www.karger.com/Article/FullText/477562

Internet

http://www.karger.com/Article/FullText/477562

Similar Items